$GILD Recent Headlines 3D Systems down on weak outlook,

New Post Public Reply Private Reply Replies (0) Message Board

Feb 12, 2014 at 11:12 AM

$GILD Recent Headlines

3D Systems down on weak outlook, CVS quits cigarettes 4:16 p.m. Feb. 5, 2014 - Saumya Vaishampayan
Time Warner, Twitter, Walt Disney are stocks to watch 5:48 a.m. Feb. 5, 2014 - Sue Chang
Tableau Software, Myriad shares rally after earnings 6:02 p.m. Feb. 4, 2014 - Wallace Witkowski
Gilead does the expected by beating earnings and sales forecasts 5:13 p.m. Feb. 4, 2014 - blogs.marketwatch.com
Updates, advisories and surprises 4:31 p.m. Feb. 4, 2014 - MarketWatch
Gilead beats sales, earnings forecasts 4:27 p.m. Feb. 4, 2014 - Russ Britt
Gilead sales forecast beats $10.93B analyst view 4:18 p.m. Feb. 4, 2014 - Russ Britt
Gilead forecasts 2014 sales of $11.3B to $11.5B 4:17 p.m. Feb. 4, 2014 - Russ Britt
Gilead Q4 revs of $3.12B beats $2.85B estimate 4:14 p.m. Feb. 4, 2014 - Russ Britt
Gilead Q4 revs. are $3.12B vs 2012's $2.59B 4:13 p.m. Feb. 4, 2014 - Russ Britt
Gilead Q4 net of 55 cents beats views by 5 cents 4:12 p.m. Feb. 4, 2014 - Russ Britt
Gilead Q4 net is 55 cents vs. 2012's 50 cents 4:11 p.m. Feb. 4, 2014 - Russ Britt
Analyst upgrades Gilead, says biotech is 'too good not to own' 2:06 p.m. Feb. 4, 2014 - blogs.marketwatch.com
Happy B-day, Facebook! Enjoy the gift of global market turmoil 7:10 a.m. Feb. 4, 2014 - blogs.marketwatch.com
Yum Brands, Take-Two, CME are stocks to watch Tuesday 5:30 a.m. Feb. 4, 2014 - Sue Chang
More positive tests for hep C drug boost AbbVie and Enanta shares 10:52 a.m. Jan. 31, 2014 - blogs.marketwatch.com
Cash ain’t trash 1:55 p.m. Jan. 28, 2014 - The Trading Deck
Beware the dead-cat bounce 1:24 p.m. Jan. 28, 2014 - Michael Ashbaugh
Beware the dead-cat bounce 1:06 p.m. Jan. 28, 2014 - Michael Ashbaugh
The market puts a few feathers in its cap 1:58 p.m. Jan. 23, 2014 - The Trading Deck

Gilead a Given for Hepatitis C Favorite 48 min ago - Barrons.com
Stock Market News for February 12, 2014 - Market News 10:06 a.m. Today - Zacks.com
Biotech Stock Roundup: Gilead's Sovaldi Impresses, EU Nod for Biogen's Tecfidera - Analyst Blog 8:27 a.m. Today - Zacks.com
Short Sellers Shy Away From Biotechs 6:04 a.m. Today - 247WallSt.com
Buy GILD Now Before Its Next Breakout 7:16 p.m. Feb. 11, 2014 - InvestorPlace.com
Gilead Sciences Inc (GILD): Today's Featured Drugs Winner 5:00 p.m. Feb. 11, 2014 - TheStreet.com
Gilead Seeks U.S. Approval - Analyst Blog 4:00 p.m. Feb. 11, 2014 - Zacks.com
Stock Market News for February 11, 2014 - Market News 10:06 a.m. Feb. 11, 2014 - Zacks.com
Gilead +2.8% on positive talk, Sovaldi would make numbers look even better 3:59 p.m. Feb. 10, 2014 - Seeking Alpha
Gilead Going to $90, or $110 2:37 p.m. Feb. 10, 2014 - 247WallSt.com
Three ETFs To Buy On The Pullback (PJP, SKYY, SPY) 8:13 a.m. Feb. 10, 2014 - Benzinga.com
Top Analyst Upgrades and Downgrades: Fairway Group, J.P. Morgan, Red Robin, Vodafone, More 7:57 a.m. Feb. 10, 2014 - 247WallSt.com
The Hep C Race Is Heating Up: AbbVie Vs. Gilead 7:47 a.m. Feb. 10, 2014 - Seeking Alpha
Weekly CEO Sells Highlight: Rocket Fuel Inc, Gilead Sciences Inc, ServiceNow Inc, and First ... 10:57 p.m. Feb. 9, 2014 - GuruFocus.com
You Can No Longer Ignore Biotech 4:32 p.m. Feb. 7, 2014 - GuruFocus.com
Is Gilead Sciences (GILD) a Great Growth Stock? - Tale of the Tape 8:38 a.m. Feb. 7, 2014 - Zacks.com
Stock Market News for February 06, 2014 - Market News 10:06 a.m. Feb. 6, 2014 - Zacks.com
Zacks Rank #1 Additions for Thursday - Tale of the Tape 9:30 a.m. Feb. 6, 2014 - Zacks.com
'Mad Money' Lightning Round: We Don't Want Molycorp 6:00 a.m. Feb. 6, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: A Matter of Distrust 7:51 p.m. Feb. 5, 2014 - TheStreet.com

Brazilian Pharmaceutical Market 2014-2024 10:03 a.m. Today - PR Newswire - PRF
Gilead Sciences to Present at Two Upcoming Investor Conferences 5:00 p.m. Feb. 10, 2014 - BusinessWire - BZX
Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Hepatitis C 4:05 p.m. Feb. 10, 2014 - BusinessWire - BZX
Gilead Sciences Announces Fourth Quarter and Full Year 2013 Financial Results 4:05 p.m. Feb. 4, 2014 - BusinessWire - BZX
Critical Alerts For Procter and Gamble, Randgold Resources, Cerner, Gilead Sciences, and Walter Energy Released By InvestorsObserver 9:31 a.m. Feb. 4, 2014 - PR Newswire - PRF
Mylan Named as Gilead's Exclusive Branded Medicines Business Partner for India 12:30 a.m. Jan. 31, 2014 - PR Newswire - PRF
Gilead Sciences to Release Fourth Quarter and Year End 2013 Financial Results on Tuesday, February 4, 2014 5:00 p.m. Jan. 28, 2014 - BusinessWire - BZX
Gilead Announces Executive Promotions 5:00 p.m. Jan. 27, 2014 - BusinessWire - BZX
European Commission Grants Marketing Authorization for Gilead’s Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection 9:09 a.m. Jan. 17, 2014 - BusinessWire - BZX
Acceptance of NDA for Review, Acquisitions of Development Rights, Earnings Release Schedulesm and New Leaders - Research Report on Gilead, Lilly, Allergan, Incyte, and Varian Medical Systems 8:00 a.m. Jan. 16, 2014 - PR Newswire - PRF
U.S. FDA Accepts New Drug Application for Gilead’s Idelalisib for the Treatment of Refractory Indolent Non-Hodgkin’s Lymphoma 8:30 a.m. Jan. 13, 2014 - BusinessWire - BZX
Biotoscana agrees to acquire United Medical to expand commercial presence in Brazil and create a leading regional specialty pharmaceutical company in South America 1:15 a.m. Jan. 13, 2014 - BusinessWire - BZX
Gilead Sciences to Present at the 32nd Annual JPMorgan Healthcare Conference on Monday, January 13 5:00 p.m. Jan. 10, 2014 - BusinessWire - BZX
Retirement Announcements, Stock Price Movements, and Scheduled Conferences Presentations - Research Report on Gilead, Aegerion, Celldex, Alnylam, and Ironwood 8:00 a.m. Jan. 9, 2014 - PR Newswire
Stock Price Movements, Conference Presentation Schedules, and Expanded Sharing of Clinical Data - Research Report on Gilead, Express Scripts, Sanofi, Agilent, and Kythera Biopharma 8:00 a.m. Jan. 8, 2014 - PR Newswire
Galectin Therapeutics Receives Patent for Combination Treatment for Liver Fibrosis 12:17 p.m. Jan. 7, 2014 - ACCESSWIRE
Notable Buzzers: Apple Inc, Stereotaxis Inc, Tiger Oil and Energy Inc, Gilead Sciences Inc 11:00 a.m. Jan. 7, 2014 - ACCESSWIRE
Gilead Sciences' Kevin Young CBE, Executive Vice President, Commercial Operations, to Retire 4:29 p.m. Jan. 6, 2014 - BusinessWire
Critical Alerts For Trina Solar, Gilead Sciences, Priceline, Akamai, and Anglogold Ashanti Released By InvestorsObserver 9:31 a.m. Jan. 2, 2014 - PR Newswire
Technical Briefing on Health Care Sector: Gilead Sciences, Halozyme Therapeutics, NPS Pharma, and InterMune 8:00 a.m. Dec. 26, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

IDEAYA's IDE101: A New Front in Cancer Battle

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Princess Cruises Launches New Era at Celebration Key

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Investors Gear Up for Lennar Class Action Lawsuit

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Portillo's Faces Class Action: Investor Losses at Stake

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Viking Ventures: Impacts of VK2735 on Obesity Examined

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

KINGRVER Boosts RV Comfort with New Water Heater Lineup

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

CVS Study: GLP-1 Drugs Effective But Costly

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...